Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Earnings & Valuation
This table compares Bluejay Diagnostics and Lucid Diagnostics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | N/A | N/A | -$6.85 million | ($11.63) | -0.11 |
| Lucid Diagnostics | $4.71 million | 43.76 | -$58.01 million | ($0.47) | -2.16 |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Bluejay Diagnostics and Lucid Diagnostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 312.56%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Bluejay Diagnostics.
Insider and Institutional Ownership
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Bluejay Diagnostics and Lucid Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -144.27% | -115.00% |
| Lucid Diagnostics | -876.72% | N/A | -116.26% |
Volatility & Risk
Bluejay Diagnostics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Summary
Lucid Diagnostics beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
